Related Experiment Video

Updated: Jun 29, 2025

Live Images of GLUT4 Protein Trafficking in Mouse Primary Hypothalamic Neurons Using Deconvolution Microscopy
08:47

Live Images of GLUT4 Protein Trafficking in Mouse Primary Hypothalamic Neurons Using Deconvolution Microscopy

Published on: December 7, 2017

9.7K

Anti-Inflammatory Effects of Glucagon-Like Peptide-1 Receptor Agonists via the Neuroimmune Axis

Susanna Fang1,2, Chi Kin Wong1

  • 1Lunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, Ontario, Canada.

DNA and Cell Biology
|April 5, 2024
PubMed

Insights

Glucagon-like peptide 1 receptor agonists (GLP-1RAs) reduce inflammation by acting on the brain's GLP-1 receptor. This highlights a key mechanism for treating inflammatory conditions and metabolic diseases.

Area of Science:

  • Pharmacology
  • Immunology
  • Neuroscience

Background:

  • Glucagon-like peptide 1 receptor agonists (GLP-1RAs) are effective in treating metabolic diseases.
  • Their anti-inflammatory properties contribute to therapeutic efficacy.
  • The precise cellular targets and pathways remain incompletely understood.

Purpose of the Study:

  • To review the literature on GLP-1RAs and inflammation.
  • To discuss the role of the brain GLP-1 receptor in mediating anti-inflammatory effects.
  • To explore implications for metabolic and inflammatory diseases.

Main Methods:

  • Literature review of studies on GLP-1RAs, inflammation, and the central nervous system.
  • Analysis of findings from Wong et al. regarding brain GLP-1R in TLR and sepsis models.
  • Synthesis of evidence on GLP-1RA mechanisms in inflammation.

Main Results:

  • GLP-1 receptor activation in the brain is crucial for the anti-inflammatory effects of GLP-1RAs.
  • This mechanism is relevant in models of Toll-like receptor (TLR) and sepsis-induced inflammation.
  • GLP-1RAs modulate inflammatory responses through central pathways.

Conclusions:

  • The brain GLP-1 receptor is a key mediator of GLP-1RA anti-inflammatory actions.
  • Targeting brain GLP-1R may offer novel therapeutic strategies for inflammatory and metabolic disorders.
  • Further research is warranted to fully elucidate these neuro-immune interactions.
Keywords:
Toll-like receptorcentral nervous systemglucagon-like peptide 1 receptor agonistsgut–brain axisinflammationsepsis

More Related Videos

Studying the Hypothalamic Insulin Signal to Peripheral Glucose Intolerance with a Continuous Drug Infusion System into the Mouse Brain08:32

Studying the Hypothalamic Insulin Signal to Peripheral Glucose Intolerance with a Continuous Drug Infusion System into the Mouse Brain

Published on: January 4, 2018

10.3K
Mixed Primary Cultures of Murine Small Intestine Intended for the Study of Gut Hormone Secretion and Live Cell Imaging of Enteroendocrine Cells09:16

Mixed Primary Cultures of Murine Small Intestine Intended for the Study of Gut Hormone Secretion and Live Cell Imaging of Enteroendocrine Cells

Published on: April 20, 2017

15.5K

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
321
Regulation of Food Intake01:30

Regulation of Food Intake

Short-term regulation of food intake primarily involves neural signals from the gastrointestinal (GI) tract, blood nutrient levels, and GI tract hormones. Communication between the gut and brain via vagal nerve fibers plays a significant role in evaluating the contents of the gut. Clinical studies have shown that protein ingestion produces a more prolonged response in these nerve fibers compared to an equivalent amount of glucose. Additionally, the activation of stretch receptors caused by GI...
228
GPCRs Regulate Adenylyl Cylase Activity01:09

GPCRs Regulate Adenylyl Cylase Activity

Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of...
5.5K
Hormones Regulating Blood Glucose01:16

Hormones Regulating Blood Glucose

Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
3.3K
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
257
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
184